News

For a total overview over all Hexvix and Photocure news, please visit www.photocure.com

Here are the latest news from Hexvix:

Photocure Completes Enrollment in US Market expansion study of Blue Light Flexible Cystoscopy (BLFC) with Cysview ®

Oslo, Norway, February 3, 2017 Photocure ASA (OSE: PHO), announced today that it has completed enrollment in its Phase 3 study with BLFC with Cysview in patients with Non Muscle Invasive Bladder cancer (NMIBC) undergoing follow up (surveillance) cystoscopy in the outpatient setting. The enrollment of 300 bladder cancer patients has secured that a minimum of 100 patients have been referred to and received repeat administrations of Blue Light Cystoscopy with Cysview in the operating room setting. In the study, Cysview was used in conjunction with the flexible KARL STORZ system. Results from the study are expected to be available mid-2017.


US REGISTRY SHOWS THAT BLUE LIGHT CYSTOSCOPY (BLC) WITH CYSVIEW®/HEXVIX® LEADS TO IMPROVED DETECTION AND CLASSIFICATION OF BLADDER CANCER

Photocure ASA (PHO-NO) announced today new data from a prospective multicenter real world study that included 338 patients, 415 BLC procedures and 1060 lesions from nine study sites in the United States. BLCC as an adjunct to white light cystoscopy (WLC) resulted in the detection of an additional 151 lesions and 45 patients uniquely with the addition of blue light. This resulted in upgrading or upstaging of 52 (15%) of the patients. Correct staging and grading impacts the management of bladder cancer patients and may have an impact on patient outcomes


BLUE LIGHT CYSTOSCOPY (BLC) WITH CYSVIEW®/HEXVIX® DECREASES THE RISK OF PROGRESSION AND RECURRENCE IN BLADDER CANCER

Oslo, Norway, November 28th, 2016 Photocure ASA announced the publication of The Comparative effectiveness of fluorescence cystoscopy versus white light cystoscopy (WLC) for initial diagnosis or surveillance of bladder cancer on clinical outcomes: Systematic review and meta-analysis in the Journal of Urology. This review, which was sponsored by the US Agency for Healthcare Research (AHRQ), concluded that Blue Light Cystoscopy with Cysview®/Hexvix® was associated with decreased risk of progression and recurrence of non-muscle invasive bladder cancer versus White Light Cystoscopy alone.


STRONG RECOMMENDATIONS FOR BLUE LIGHT CYSTOSCOPY WITH HEXVIX® IN NEW FRENCH GUIDELINES

Oslo, Norway, November, 21 2016: Photocure ASA (OSE:PHO) announced today that new 2016 French National Guidelines for the management of Bladder Cancer includes its Blue Light Cystoscopy (BLC) with Hexvix®.  The new guidelines have been presented on November 17th, during Association of French Urologists (AFU) National Meeting, Paris, France published on line in Progres en […]


NEW DATA PRESENTED ON BLUE LIGHT CYSTOSCOPY WITH CYSVIEW®/HEXVIX® AT THE SOCIÉTÉ INTERNATIONALE D’UROLOGIE (SIU) 2016 ANNUAL MEETING

Oslo, Norway, October 25, 2016 Photocure ASA announced that new data on Blue Light Cystoscopy with Cysview®/Hexvix® were presented at the Société Internationale d’Urologie (SIU) Annual meeting, October 20th to 23rd, Buenos Aires, Argentina: an ePoster from a US registry study and an ePoster video on Blue Light Flexible Cystoscopy.